What sector does West Pharmaceutical Services belong to?

West Pharmaceutical Services operates in the Health Care sector, specifically the Health Care Supplies industry, and is listed on the US markets.

What is the current share price of WST?

As of the latest available quote, WST traded at $346.23. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of WST?

West Pharmaceutical Services has a price-to-earnings (P/E) ratio of about 44.27. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of WST?

The market capitalisation of West Pharmaceutical Services is approximately $25.17B.

Is West Pharmaceutical Services profitable?

For its latest reported financial year, West Pharmaceutical Services recorded a net profit margin of about 16.06%.

Does WST pay a dividend?

West Pharmaceutical Services currently has a dividend yield of about 0.25%.

What is the return on equity (ROE) of WST?

West Pharmaceutical Services has a return on equity (ROE) of about 16.51%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of WST?

Over the past 52 weeks, WST has traded between a low of $223.83 and a high of $386.00.

West Pharmaceutical Services

WST US Health Care Health Care Supplies

S&P 500

$346.23

+0.58%

Delayed · cached 15 min

Fair value analysis

WST

West Pharmaceutical Services

$346.23

Close used for this calculation

$127.37Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

54/100

Profitability19/25

Returns8/25

Balance Sheet25/25

Efficiency2/25

Growth6/25

Good

Quality radar

Consensus fair value

$127.37

Above FV

▼ -63.2% against the close used

Model range $80.02 – $172.25

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$80.02Fair value$127.37Bull$172.25

FairClose

52-week traded range

52W low $230.9552W high $365.74

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

West Pharmaceutical Services closed at $346.23, 171.8% above the consensus fair value of $127.37 drawn from 8 valuation models.

Financial DNA score 54/100 — Good. P/E of 51.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$128.00

-63.0%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

$80.02

-76.9%

√(22.5 × EPS × BVPS)

EPS=6.79, BVPS=41.92 · outside Graham range (P/E 51, P/B 8.3) — asset-light, treat as a rough floor

P/E Fair Value

$135.80

-60.8%

EPS × 20x (sector P/E)

EPS=6.79, Sector P/E=20x

Peter Lynch (PEG)

$89.08

-74.3%

EPS × Growth% (PEG = 1 is fair)

EPS=6.79, g=13.1%

EV/EBITDA

$172.25

-50.2%

(EBITDA × 16.6x − Net Debt) ÷ Shares

EBITDA=756.3M

Book Value (P/B)

$110.14

-68.2%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=41.92, ROE=16.5%, g=6%, r=10%

Reverse DCF

$346.23

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 19.8% | Historical: 13.1%

Margin of Safety

$85.96

-75.2%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=114.61, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer